Share Market Newspaper

(Albany, US), September 21, 2026 – DelveInsight’s “Chronic Periodontitis Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Chronic Periodontitis, historical and forecasted epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Curious to know what’s driving the Chronic Periodontitis market through 2036?

Download the report to understand the latest Chronic Periodontitis market trends and forecasts – https://www.delveinsight.com/report-store/chronic-periodontitis-market

Key Takeaways from the Chronic Periodontitis Market Report

• The chronic periodontitis market is expected to grow significantly by 2036.

• Approved products for chronic periodontitis include ARESTIN (minocycline hydrochloride microspheres) and REGROTH Dental Kit (trafermin), while the pipeline remains sparse in the 7MM, with GPV381 in development outside major markets, highlighting the need for disease-modifying innovation.

• Severe periodontal disease affects more than 1 billion people worldwide, representing a substantial global oral-health burden.

• Secondary research indicates that approximately 42% of dentate US adults aged 30 years and older are affected by periodontitis.

• In Japan, periodontitis affects nearly half of the population, with an estimated prevalence of 49.4%.

• In February 2024, Denteric reported the dosing of the first subjects in its first-in-human safety study of GPV381, an investigational therapy being developed for the treatment of severe periodontal disease.

Gain a competitive edge in the Chronic Periodontitis Market by exploring our in-depth analysis @ Chronic Periodontitis Market

Chronic Periodontitis Market Overview

Chronic periodontitis is a long-standing inflammatory disease of the supporting structures of the teeth, characterized by progressive periodontal attachment loss and alveolar bone destruction, leading to deep periodontal pockets, tooth mobility, and eventual tooth loss if left unaddressed. Symptoms include gingival inflammation and bleeding, periodontal pocket formation, progressive attachment and bone loss, and tooth mobility. The disease is largely caused by pathogenic oral bacteria that accumulate with poor oral hygiene, forming plaque that hardens into calculus, and is further influenced by host immune dysregulation, genetic susceptibility, smoking, and systemic risk factors.

Chronic periodontitis is diagnosed through clinical evaluation of probing depths, attachment loss, and bleeding on probing, supported by intraoral dental X-rays or an orthopantomogram (OPG) to assess alveolar bone loss and deep periodontal pockets.

Discover key developments and opportunities in the Chronic Periodontitis Market @ Chronic Periodontitis Market

Chronic Periodontitis Market Key Growth Drivers

• Rising Global Prevalence of Periodontal Disease: Chronic periodontitis represents a substantial global oral-health burden, with severe periodontal disease affecting more than 1 billion people worldwide. The increasing disease burden is expected to support demand for periodontal diagnostics, therapeutics, and professional dental care.

• Growing Geriatric Population: The prevalence of severe periodontal disease increases with age, peaking around the mid-50s and remaining elevated among older adults. Population aging is therefore expected to expand the pool of patients requiring long-term periodontal management and tooth-preservation treatments.

• Increasing Prevalence of Diabetes: Diabetes is closely associated with the development and progression of periodontal disease, while periodontitis can also complicate glycemic management. Growing awareness of this two-way relationship is encouraging greater integration of dental examinations and periodontal care into diabetes management.

• High Tobacco Consumption and Other Lifestyle Risk Factors: Tobacco use is a major behavioral risk factor for periodontal disease, while poor oral hygiene, unhealthy diets, and other lifestyle factors can further increase oral-health risks. Continued exposure to these factors contributes to the underlying patient pool for chronic periodontitis treatment.

Chronic Periodontitis Epidemiology

The epidemiology section provides insights into the historical and current Chronic Periodontitis patient pool and forecasted trends for each of the seven major markets. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders, and also provides the diagnosed patient pool and its trends along with the assumptions undertaken. The report covers historical as well as forecasted Chronic Periodontitis epidemiology in the 7MM, covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan, from 2022 to 2036.

• In the US, 8.7% of adults have mild periodontitis, 30.0% have moderate disease, and 8.5% are affected by severe periodontitis, reflecting a substantial burden across disease severities.

• Across Europe, chronic periodontitis prevalence rises sharply from the 30s, peaks in adults aged 65–74 years, and remains rare in younger populations, which account for only around 1.7% of cases.

• In the UK, periodontitis affects nearly half of the adult population and approximately 60% of individuals aged over 65 years, underscoring its status as one of the most prevalent chronic inflammatory diseases.

• In the US, periodontitis disproportionately affects men (approximately 57%) compared with women (around 39%), underscoring a clear gender-related difference in disease burden.

• In Japan, periodontitis affects nearly half of the population, with an estimated prevalence of 49.4%.

Explore further details on the Chronic Periodontitis Market @ Chronic Periodontitis Market

Chronic Periodontitis Treatment

The treatment landscape for chronic periodontitis includes non-surgical scaling and root planing with adjunctive antimicrobials, and surgical options such as periodontal flap procedures and regenerative grafting, supported by patient education on oral hygiene.

Chronic Periodontitis Drug Analysis

The drug chapter of the report encloses a detailed analysis of marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also covers clinical trial details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic Periodontitis Marketed Drugs

• ARESTIN (Minocycline Hydrochloride): Bausch Health

ARESTIN (minocycline hydrochloride microspheres) is a locally delivered, sustained-release antibiotic placed into periodontal pockets after scaling and root planing, providing targeted antimicrobial activity to reduce pathogenic bacteria and support periodontal pocket depth reduction. In February 2001, the US FDA approved ARESTIN as an adjunct to scaling and root planing in the treatment of adult periodontitis.

• REGROTH Dental Kit (trafermin): Kaken

REGROTH Dental Kit (trafermin) is a locally applied recombinant basic fibroblast growth factor formulation used during periodontal surgery to stimulate periodontal tissue regeneration by promoting angiogenesis and proliferation of periodontal ligament and alveolar bone–forming cells at defect sites. In October 2016, Kaken Pharmaceutical received regulatory approval in Japan for REGROTH Dental Kit for periodontal regeneration in patients with periodontitis involving alveolar bone destruction.

Chronic Periodontitis Emerging Drugs

• GPV381: Denteric

GPV381, developed by Denteric, is an investigational immunotherapy for periodontitis that targets key virulence factors of Porphyromonas gingivalis, aiming to modulate host–pathogen interactions and address underlying inflammatory drivers of periodontal tissue destruction. GPV381 is currently in Phase I clinical development. In February 2024, Denteric reported the dosing of the first subjects in its first-in-human safety study of GPV381.

Chronic Periodontitis Market Outlook

The market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Periodontitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. It gives thorough detail on the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and the views of key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Gain a competitive edge in the Chronic Periodontitis Market by exploring our in-depth analysis @ Chronic Periodontitis Market

Scope of the Chronic Periodontitis Market Report

• Study Period: 2022–2036

• Geographies Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan

• Key Companies: Bausch Health, Kaken Pharmaceutical, Denteric, and others

• Key Therapies: ARESTIN (minocycline hydrochloride microspheres), REGROTH Dental Kit (trafermin), GPV381, and others

Table of Content

1. Key Insights

2. Executive Summary of Chronic Periodontitis

3. Competitive Intelligence Analysis for Chronic Periodontitis

4. Chronic Periodontitis: Market Overview at a Glance

5. Chronic Periodontitis: Disease Background and Overview

6. Patient Journey

7. Chronic Periodontitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Periodontitis Unmet Needs

10. Key Endpoints of Chronic Periodontitis Treatment

11. Chronic Periodontitis Marketed Products

12. Chronic Periodontitis Emerging Therapies

13. Chronic Periodontitis: Seven Major Market Analysis

14. Attribute Analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chronic Periodontitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-periodontitis-market